ANTI-EGFR/HIGH AFFINITY NK-CELLS COMPOSITIONS AND METHODS FOR CHORDOMA TREATMENT
Chordoma is treated in a patient by co-administration of an anti-EGFR antibody and high affinity NK cells (haNK). Most preferably, the antibody is non-covalently bound to a high affinity variant of a CD16 receptor or administered before transfusion of the haNK cells to so target the chordoma cells for cytotoxic cell killing by the haNK cells.
1 - 75 . (canceled)
76 . A method of treating chordoma comprising co-administering an anti-EGFR antibody, Alt-803, and high affinity NK (haNK) cells to a patient in need thereof at a dosage effective to treat the chordoma.
77 . The method of claim 76 , wherein the method further comprises providing an immune therapy to the patient.
78 . The method of claim 77 , wherein the immune therapy comprises administration of a recombinant yeast or recombinant virus expressing a patient- and tumor-specific neoepitope.
79 . The method of claim 76 , wherein the method further comprises providing a chemotherapy to the patient.
80 . The method of claim 79 , wherein providing the chemotherapy comprises administering at least one of aldoxorubicin, cyclophosphamide, irinotecan, gemcitabine, capecitabine, 5-FU, FOLFIRI, FOLFOX, and oxiplatin.
81 . The method of claim 76 , wherein the method further comprises providing a radiotherapy to the patient.
82 . The method of claim 76 , wherein the anti-EGFR antibody is a monoclonal antibody.
83 . The method of claim 76 , wherein the anti-EGFR antibody is cetuximab.
84 . The method of claim 76 , wherein the anti-EGFR antibody is administered at a dosage of between 100 mg/m 2 and 1,000 mg/m 2 .
85 . The method of claim 76 , wherein the anti-EGFR antibody is bound to a high-affinity CD16 that is expressed on the surface of the haNK cells.
86 . The method of claim 76 , wherein the haNK cells are administered at a dosage of between 5×10 5 cells/kg and 5×10 8 cells/kg.
87 . The method of claim 76 , wherein the haNK cells are NK92 derivative that further express recombinant IL2.
88 . The method of claim 76 , wherein the haNK cells are irradiated at a radiation dose of at least 500 cGy before administration.
89 . The method of claim 77 , wherein providing the immune therapy comprises administering a recombinant yeast or recombinant virus expressing brachyury.